An international partnership that funds vaccines for children in poor countries will decide whether to also start investing in vaccinations to protect adult women.

The board of the Global Alliance for Vaccines and Immunisation (GAVI), which is backed by the Gates Foundation, is meeting in Geneva on a proposed $3.5 billion vaccine investment strategy specifying diseases it will tackle from 2009 to 2020.

A vaccine to immunise women against the human papilloma virus (HPV), the main cause of cervical cancer, and one to prevent miscarriages or birth defects caused by rubella virus, are among the seven listed in the proposal to the board.

Merck & Co and GlaxoSmithKline have both recently introduced rival HPV vaccines, called Gardasil and Cervarix, that are seen by analysts as multibillion-dollar sellers but are expensive for developing countries.

GAVI’s new spending strategy would also prioritise vaccines to protect children in impoverished nations against cholera, typhoid, rabies, meningitis A and Japanese encephalitis, according to a draft obtained by Reuters.

“The portfolio … has the potential to avert approximately 2 million deaths across different age groups and all GAVI countries within 10 years,” according to the Geneva-based group, which supports immunisations in more than 70 countries, from Afghanistan to Zimbabwe.

“Moreover, with HPV and rubella vaccines, GAVI would have an opportunity to protect vulnerable women against a serious and fatal disease and congenital anomalies of their newborns,” it said in a report to the board, whose members include the World Health Organisation, UNICEF, the World Bank and vaccine makers.

The vaccination programmes GAVI already supports for diphtheria, tetanus, whooping cough and measles are thought to prevent 2.5 million child deaths a year.

Such campaigns, as well as those for hepatitis B, yellow fever, pneumococcal disease and rotavirus, would continue regardless of whether the new investment strategy is backed in full, a spokesman said.

GAVI was launched in 2000 as a private-public partnership. Its major backers include the Bill & Melinda Gates Foundation, which gave it $1.5 billion, and governments including Britain, France, Norway, South Africa and Brazil.

The vaccines GAVI supports through advance market commitments and other programmes are made by pharmaceutical companies including Crucell, Novartis, GlaxoSmithKline, Merck & Co, Sanofi Pasteur and Wyeth.